A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis

Trial Profile

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2016

At a glance

  • Drugs WF 10 (Primary)
  • Indications Allergic rhinitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms 2014 WF10 Trial
  • Sponsors Nuvo Research
  • Most Recent Events

    • 08 Jun 2015 Results published in a Nuvo Research media release.
    • 08 Jun 2015 Status changed from active, no longer recruiting to completed according to a Nuvo Research media release.
    • 05 Mar 2015 Top-line results discussed in Nuvo Research media release and compared with results of the 2010 trial; unblinded follow-up will continue for 24 weeks post-treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top